WO2004041181A3 - Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration - Google Patents

Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration Download PDF

Info

Publication number
WO2004041181A3
WO2004041181A3 PCT/US2003/034535 US0334535W WO2004041181A3 WO 2004041181 A3 WO2004041181 A3 WO 2004041181A3 US 0334535 W US0334535 W US 0334535W WO 2004041181 A3 WO2004041181 A3 WO 2004041181A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
macular degeneration
cytokine inhibitory
compositions
selective cytokine
Prior art date
Application number
PCT/US2003/034535
Other languages
French (fr)
Other versions
WO2004041181A2 (en
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Jerome B Zeldis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Jerome B Zeldis filed Critical Celgene Corp
Priority to EP03779423A priority Critical patent/EP1567148A4/en
Priority to BR0315889-6A priority patent/BR0315889A/en
Priority to MXPA05004486A priority patent/MXPA05004486A/en
Priority to JP2004550274A priority patent/JP2006509743A/en
Priority to AU2003285107A priority patent/AU2003285107B2/en
Priority to CA002504263A priority patent/CA2504263A1/en
Priority to NZ540185A priority patent/NZ540185A/en
Publication of WO2004041181A2 publication Critical patent/WO2004041181A2/en
Publication of WO2004041181A3 publication Critical patent/WO2004041181A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
PCT/US2003/034535 2002-10-31 2003-10-31 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration WO2004041181A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP03779423A EP1567148A4 (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
BR0315889-6A BR0315889A (en) 2002-10-31 2003-10-31 Method of treating, preventing or controlling macular degeneration and pharmaceutical composition
MXPA05004486A MXPA05004486A (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration.
JP2004550274A JP2006509743A (en) 2002-10-31 2003-10-31 Methods of using selective cytokine inhibitors for the treatment and management of macular degeneration and compositions containing the same
AU2003285107A AU2003285107B2 (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
CA002504263A CA2504263A1 (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
NZ540185A NZ540185A (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42290002P 2002-10-31 2002-10-31
US60/422,900 2002-10-31

Publications (2)

Publication Number Publication Date
WO2004041181A2 WO2004041181A2 (en) 2004-05-21
WO2004041181A3 true WO2004041181A3 (en) 2005-02-17

Family

ID=32312567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034535 WO2004041181A2 (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration

Country Status (12)

Country Link
EP (1) EP1567148A4 (en)
JP (1) JP2006509743A (en)
KR (1) KR20050062649A (en)
CN (1) CN1731997A (en)
AU (1) AU2003285107B2 (en)
BR (1) BR0315889A (en)
CA (1) CA2504263A1 (en)
MX (1) MXPA05004486A (en)
NZ (1) NZ540185A (en)
TW (1) TW200418455A (en)
WO (1) WO2004041181A2 (en)
ZA (1) ZA200503468B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
EP2663549B1 (en) * 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
KR101908330B1 (en) 2017-02-17 2018-10-16 인제대학교 산학협력단 Novel anti-vascular endothelial growth factor antibody and composition for preventing or treating age-related macular degeneration comprising thereof
AU2019382044A1 (en) * 2018-11-14 2021-06-03 Zhuhai Qiwei Bio-Technology Ltd. Animal models, screening methods, and treatment methods for intraocular diseases or disorders
EP3886852B1 (en) * 2018-12-03 2024-01-31 Smilebiotek Zhuhai Limited Octyl gallate and esters thereof of for use in the treatment and prevention of age-related macular degeneration caused by bacillus megaterium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577589A (en) * 1897-02-23 Valve for explosive-engines
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
CN1265590A (en) * 1997-07-31 2000-09-06 赛尔金有限公司 Substituted alkanohydroxamic acid and method of reducing TNF 'alpha' levels
KR100699968B1 (en) * 1998-05-11 2007-03-28 더 칠드런스 메디칼 센터 코포레이션 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
JP2000159761A (en) * 1998-11-30 2000-06-13 Yoshio Takeuchi Fluorothalidomide
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
CN1646131A (en) * 2002-04-19 2005-07-27 史密丝克莱恩比彻姆公司 Novel compounds
EP1556033A4 (en) * 2002-05-17 2006-05-31 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
AU2003228509B2 (en) * 2002-10-15 2008-06-26 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRESSLER N.M.: "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1", ARCHIVES OF OPHTHALMOLOGY, vol. 117, no. 10, 1999, CHICAGO, pages 1329 - 1345, XP000853866 *
HUNT D.W.C.: "Rostaporfin (Miravant Medical Technologies)", DRUGS, vol. 5, no. 2, 2002, pages 180 - 186, XP008041591 *
OHNO-MATSUI K. ET AL.: "Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 189, no. 3, 2001, pages 323 - 333, XP002904768 *
See also references of EP1567148A4 *

Also Published As

Publication number Publication date
EP1567148A2 (en) 2005-08-31
KR20050062649A (en) 2005-06-23
AU2003285107A1 (en) 2004-06-07
MXPA05004486A (en) 2005-07-26
AU2003285107B2 (en) 2008-01-10
BR0315889A (en) 2005-10-04
TW200418455A (en) 2004-10-01
CN1731997A (en) 2006-02-08
ZA200503468B (en) 2006-10-25
WO2004041181A2 (en) 2004-05-21
JP2006509743A (en) 2006-03-23
EP1567148A4 (en) 2010-09-15
NZ540185A (en) 2008-01-31
CA2504263A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
WO2005043971A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
WO2004037207A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
MX358515B (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes.
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
IL178591A (en) 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for the treatment and management of myelodysplastic syndromes
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
WO2004034962A3 (en) Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
WO2004043378A3 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
MX2011008132A (en) Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis.
WO2004041190A3 (en) Composition for the treatment of macular degenration
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2004041181A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
WO2005110085A3 (en) Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
WO2005046594A3 (en) Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
WO2004080393A3 (en) Selective cytokine inhibitory drugs for treating disorders of the central nervous system
WO2005094218A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2004043336A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
WO2004029025A3 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004486

Country of ref document: MX

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2504263

Country of ref document: CA

Ref document number: 2004550274

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005/03468

Country of ref document: ZA

Ref document number: 200503468

Country of ref document: ZA

Ref document number: 1020057007608

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 168313

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003285107

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 540185

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 540185

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003779423

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057007608

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038A80906

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003779423

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0315889

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2003285107

Country of ref document: AU

Date of ref document: 20031031

Kind code of ref document: B